Prof Jagat Kanwar

STAFF PROFILE

Position

Professor In Nanomedicine

Faculty

Faculty of Health

Department

School of Medicine

Campus

Geelong Waurn Ponds Campus

Qualifications

Bachelor of Science, , 1984
Master of Science, Punjabi University, 1988
Doctor of Philosophy, Postgrad Inst of Med Edu & Res, 1993

Biography

Degree/Award Year Discipline/Field Organisation and Country

  1. PhD 1993: Biotechnology (Medical Biochemistry & Immunology): Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
  2. MSc 1988: Medical Biochemistry: College of Basic Sciences, PAU, Ludhiana, Punjab, India
  3. BSc 1984: Medical Sciences: Himachal Pradesh University, Shimla, Himachal Pradesh, India

Current and previous appointment

  • BEd-Sc (Bachelor of Education Science) 1985: Guru Nanak Dev University, Amritsar, Punjab, India
  • Research Fellow The University of Auckland, NZ Department of Molecular Medicine & Pathology Jan 1997-Dec 2001
  • Senior Scientist/Senior Research Fellow The University of Auckland, NZ Department of Molecular Medicine & Pathology Jan 2001-March 2006
  • Associate Professor of Immunology & Cell Biology, Team Leader of Nanomedicine Laboratory (NLIMBR) Deakin University, Australia Centre for Biotechnology and Interdisciplinary Sciences (BioDeakin), March 2006-2013
  • Professor of Nanomedicine, Team Leader of Nanomedicine Laboratory of Immunology & Molecular Biomedical Research (NLIMBR) Deakin University, Australia School of Medicine, Faculty of Health 2013- to date

 

Professor Jagat Kanwar has received his PhD in 1992 from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University, Australia, in 2006, he was Senior Scientist in the University of Auckland, New Zealand. We seek to explore the roles of molecular mediators, antioxidants and cellular communication in the pathophysiological mechanisms of chronic inflammatory, microbial diseases and cancer. Our research combines immunology with state of the art and cutting edge techniques in molecular biology, biochemistry, nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed. Our objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. We carry out both academic and commercial research projects and develop new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems for the prevention of human diseases like cancer, vision abnormalities, infectious, inflammatory bowel disease (IBD), neurodegenerative, osteoarthritis, cardiovascular and pulmonary diseases. NLIMBR through national and international collaborations aims in near future to translate discoveries into new approaches for the diagnosis, treatment, and prevention of human diseases.

Our recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with anti-tumour proteins, peptides, siRNA, shRNA, miRNA, LNA modified nucleic acids, and/or drug molecules which specifically target cells. We are developing nano-medicinal based war against cancer/inflammatory cells with double targeted nano-bullet nanocapsules that specifically induce their traumatic death in cancer cells, chronic inflammatory cells and transformed cloudy myofibroblast cells, and spare normal body cells. The success behind our team is, working as a unit in creating and maintaining a healthy and work friendly environment.

Read more on Jagat's profile

Biography summary

Professor Kanwar is the group leader and laboratory head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research in School of Medicine, Faculty of Health at Deakin University. His earlier research (for nearly a decade in New Zealand) has focused on studying pathophysiology and devising new treatments mainly for cancer and chronic inflammatory diseases. Prof. Kanwar is currently working on nanotechnology/nanomedicine based protein/peptide, aptamers and his research approach employs monotherapy (gene therapy, immunotherapy) and combinational therapy with commercially available chemotherapeutic agents including LNA-aptamers (RNA/DNA), peptides and other biomolecules such as siRNA, miRNA, aptamers, proteins, siRNA, miRNA and their chimera (LNA-aptamer chimera with siRNA/miRNA delivery for targeting expression of survivin (the validated anti-cancer target), HIF-1 and apoptotic signalling molecules’ in cancer and chronic inflammation.

 

We are discovering novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in regeneration, apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of osteoarthritis, atherosclerosis, myocardial infarction, ocular inflammations, corneal haze, age related macular degeneration, glaucoma and ocular drug delivery. Apart from these we also work on microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes.

Career highlights

March 2006 - ongoing: Associate Professor of Immunology & Cell Biology, Institute of Technology Research and Innovation, Deakin University, Australia
Jan 2002: Senior Scientist/Senior Research Fellow, The University of Auckland, Auckland, NZ
Jan 1997: Research Fellow, The University of Auckland, Auckland, NZ

Research interests

Professor Jagat Kanwar is the group leader and laboratory head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR) in School of Medicine, Faculty of Health at Deakin University. He has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He is an immunologist, molecular biologist and cell biologist. He has extensive training and expertise in studying the molecular mechanisms and in devising treatments for human diseases like cancer (colon, breast, liver, prostate and retinoblastoma) and chronic inflammatory diseases such as asthma, atherosclerosis, inflammatory bowel disease (IBD), arthritis, multiple sclerosis including corneal haze, age related macular degeneration (AMD) in both in vivo and in vitro models.

Current Research Aims:
An immense focus of the group is to develop non-conventional therapeutics involving compounds for cancer and other inflammatory diseases. Nanomedicine is the need for the day to develop, synthesise and characterize of nanoformulations that can achieve a more targeted and specific delivery system is being carried out in the NLIMBR laboratory. Extensive research is carried out for development and physio-chemical characterization of biodegradable and biocompatible drug delivery vehicles. Novel targeted delivery systems possessing enhanced permeation retention effect, stability and narrow size range have been successfully synthesised. A number of other developments including microfluidics, nanodevices, nanosensers and microchips for targeted delivery and diagnosis are also our major interests. The principle aim is to achieve a system where there is a diagnostic and therapeutic approach to target cancer and other inflammatory conditions. Recently microfluidic systems being worked upon are targeting an approach to less time consuming and more economic methods for cancer and microbial infection diagnosis.

Teaching interests

Interests in innovations in medical biotechnology, nanotechnology and nanomedicine teachings

Units taught

  • 2005-2016: HMM302 - Innovations in Medical Biotechnology in Faculty of Health.
  • 2006-2012: SEK320 Nanobiotechnology -IFM-1-2012
  • 2008-2012: SEK302 Nanomedicine (Unit Chair Semester 2)
  • 2006-2011: SBB323 Immunology (Unit Chair Semester 2)

Knowledge areas

CANCERS: Development of locked nucleic acid (LNA) modified aptamers/siRNA nanocapsules based multimodular therapy to target cancer drug resistance stem cells and monitor tumours by real-time live imaging. Survivin inhibition has come across as a powerful approach for inducing drug sensitivity and inhibiting metastasis. Our group has shown that survivin inhibition using more stable locked nucleic acid (LNA) modified siRNA to survivin and cell permeable dominant negative survivin (SurR9-C84A) protein, led to downregulation of multidrug resistant (MDR) markers including survivin and induced drug sensitivity in sorted “cancer cells” as well as “cancer drug-resistant stem cells”. Our group also established orally administered nanocapsules/nanocarriers (NCs) encapsulated with super-paramagnetic iron oxide (Fe3O4)-saturated bovine lactoferrin (bLf) and zinc-ferrite saturated bLf (ZnxFe3-xO4-bLf) as theranostics for real-time live imaging in colon, prostate and breast tumours developed and atherosclerosis.

ARTHERITIS: Development of inflamed joints targeted by nanocapsules for the treatment of rheumatoid arthritis. Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that causes painful joint inflammation. RA is also referred to as a systemic illness that affects multiple organs such as lungs, eyes and if poorly treated leads to permanent joint damage, deformity, loss of function and disability. RA is incurable and poses a significant health burden in terms of personal, social and economic losses in Australia and worldwide. Current anti-RA drugs have severe side effects. There is presently an unmet need for a safe drug that is disease modifying and targets joint inflammatory disease progression. Recently, we designed, tested and patented biodegradable, non-toxic nanocapsules/nanocarriers (NCs) as a smart oral drug delivery system (Kanwar JR & Kanwar RK. “Nanoparticle” patent WO2012/145801).
 

CORNEAL HAZE/SCARRING: Corneal haze also known as scarring is caused by microbial infections, dry eyes, contact lenses, chemical trauma, physical agents, recent trend of “refractive laser surgery” and accidents including terrorism and wars. It is one of the leading cause of global blindness according to a recent World Health Organization report. In addition, infections such as trachoma, a chronic keratoconjunctivitis caused by Chlamydia trachomatis, which leads to haze/scarring and blinding, is an endemic in Australia, particularly in indigenous people and remote communities. Scarring is also a major issue after all types of surgeries and injuries due to TGF-β induction from the above mentioned conditions, that transform normal transparent corneal keratocytes into cloudy myofibroblast cells which overexpress survivin and α-smooth muscle actin (α-SMA). Recently we fabricated ultra-small algal chitosan nanoparticles (US CS NPs) for efficient delivery of Trichostatin-A (TSA) and cell permeable recombinant dominant-negative survivin protein tagged with poly-arginine (R9 carrier peptide) named SurR9-C84A, and bovine lactoferrin (bLf) to ocular tissues through topical administration to prevent carbendazim-induced toxicity. US CS NPs could be explored for their potential for delivering various ocular drugs through topical administration for other eye diseases including cataract, glaucoma and age-related macular degeneration. After the award of NHMRC grant on “corneal haze” we developed models for haze, glaucoma and age-related macular degeneration (AMD) and cataract.

DEVICES FOR DELIVERY AND DIAGNOSIS: Recently our group is focused on exploiting various Lab-on-a-Chip, or Microfluidic devices used in biomedical diagnostics for cancer, infectious, inflammatory diseases.

Conferences

National and international recognition: Invited speaker/conference chair/ conference organizing: Reflecting the recognition of Prof. Kanwar’s contribution to the biomedical research, he has been invited to national and international scientific meetings as a keynote speaker, for plenary lecture and/or symposium Chair or co-chair in more than 45 international conferences held in US, Australia, China, India, Iran, Hong Kong, UK and Singapore, in the last 5 years. Prof. Kanwar has organized more than 28 conferences in the field of nanomedicine, nanotechnology, immunology, cancer and biotechnology. In 2015 and 2016, he is organizing 3 new conferences on nanomedicine, pharmacology and biotechnology.

Professional activities

Professional involvement: He was invited for “Australian Science meets Policymakers”, Canberra and for the Integrative Medicine Education and Research (IMER) Group. Editorial Board role for 32 journals & Manuscript Reviewer for >120. He is the member of over 48 scientific committees and societies including American Chemical Society (ACS), American Association for Cancer Research (AACR), Australasian Society for Immunology (ASI), Australasian Integrative Medicine Association (AIMA), American Association of Nanomedicine, American Nano-Society, Australian Centre for Nanomedicine (UNSW), British Society for Nanomedicine, American Dairy Science Association, International Society of Aptamers (INSOAP) and The Australian Nanotechnology Network.

Teaching Interests:
Prof. Kanwar has supervised 5 Honours, 5 Master of Science and 15 Ph.D. students to graduation.  Currently, he has 4 visiting researchers, 8 Ph.D. students under his guidance, and provides co-supervision to 18 Ph.D. students. These students are working in exploring the roles of molecular mediators/cellular communication in the pathophysiological mechanisms of cancers (colon. breast, liver and brain) and chronic inflammatory diseases and devising their treatments, diagnostic biomarkers in the area of nanobiotechnology at Deakin, Australia, Deakin India Research Initiative (DIRI) in India. Several of these students have won conference presentation awards and international fellowships.

Professor Kanwar is also the unit chair for Innovations in Medical Biotechnology course.
• Innovations in Medical Biotechnology in Faculty of Health for 2 years HMM302.
• SEK320 - Nanobiotechnology - SEK320_TRI-1_2012

Media appearances

http://www.deakin.edu.au/research/stories/2012/06/25/the-fight-against-cancer
http://www.deakin.edu.au/itri/biodeakin/news/2011/02/01/biodeakin-researchers-receive-international-funding-to-develop-novel-anti-cancer-agent-and-anti-microbials
http://www.deakin.edu.au/research/stories/2010/05/13/deakins-research-pitch-in-india-continues-to-grow
http://www.deakin.edu.au/research/stories/2009/12/01/good-old-milk-as-a-cure-for-cancer
http://www.gsdm.com.au/newsletters/deakin/April09/4.html
http://www.gsdm.com.au/newsletters/deakin/dec09/6.html

Awards

Professor Kanwar has published more than 175 peer-reviewed original research papers. His papers in Gene Therapy, Journal of National Cancer Institute (JNCI) and Cancer Research have been cited 194, 137 and 82 times respectively. Prof Kanwar’s research is of high quality and highly relevant: 25 of his peer-reviewed publications have been cited more than 450 times till date. He has attracted AU$ 6 million in grant funding from Government funding agencies and AU$ 2.5 million from private funding agencies. His work has generated 12 patents/PCTs. Five of these patents have been licensed for commercialisation to biotech companies Antisoma, UK; Neurenpharma and NeuronZ, NZ. His research findings led to the development of novel ice-cream product ‘ReCharge’ with bovine lactoferrin and iron saturated milk lactoferrin as key ingredient and designated as the first medical food. It is showing promising results in phase II clinical trials for combating drug induced immunosuppression and gut damage in patients undergoing anticancer chemotherapy. One of his anti-cancer drug (anti-vascular DMXAA) is in the Sigma catalogue. He has been invited as a speaker in over 45 conferences and chaired several sessions on Immunology, Nanotechnology, Nanomedicine and Biotechnology. CIA' and his team have extensive experience in animal models and cancer biology. He has provided consultancies to more than 8 BioPharma companies including New Zealand Dairy Board, NeuronZ & Fonterra Corporation Limited, Auckland, New Zealand, Interpath Pty Ltd Australia, The Warrnambool Cheese & Butter Factory Company Limited, and 3 Indian Biotechnology based companies.

PATENTS
Web link: Patents weblink
(search for "Applicant name" Jagat Kanwar/Rupinder Kanwar)
1. WO2012145801 (NANOPARTICLE)
2. WO2006/054908
3. WO 2008/140335
4. WO 2008/079030
5. WO 2000/076497
6. WO 2002/030447
7. WO 2002/030448
8. WO 2004/009131
9. WO 2007/055599
10. WO 2006/112739
11. WO 2006/112738
12. WO 2005/107736

Projects

  1. Molecular regulation of survivin targeted nano-therapy in advanced colon, breast and prostate cancer
  2. Neem plant based Nano-Biopesticide and targeting cancers
  3. Nanoparticle encapsulated bacteriophage for the treatment of Salmonella infection
  4. Development in vitro and in vivo models for treatment of Aged macular degeneration
  5. Anti-cancer activities of dominant negative survivin (in the form of a nanoparticles), an alternative treatment for colon cancer
  6. Novel ophthalmic topical formulation targeting molecular pathogenesis of corneal haze
  7. Multi-targeted nanomedicine based therapy for treating corneal haze and cataract

Publications

Filter by

2016

Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells

Dr Kislay Roy, Mr Yogesh Patel, Dr Rupinder Kanwar, Dr Rangam Rajkhowa, Prof Xungai Wang, Prof Jagat Kanwar

(2016), Vol. 11, pp. 25-44, International journal of nanomedicine, Macclesfield, Eng., C1

journal

Radioprotective activity of Polyalthia longifolia standardized extract against x-ray radiation injury in mice

Subramanion L. Jothy, Tamio Saito, Prof Jagat Kanwar, Yeng Chen, Azlan Aziz, Yin-Hui leong, Sreenivasan Sasidharan

(2016), Vol. 32, pp. 150-161, Physica medica, Amsterdam, The Netherlands, C1

journal

Comparative activities of milk components in reversing chronic colitis

Prof Jagat Kanwar, Dr Rupinder Kanwar, S Stathopoulos, Neill Haggarty, Alister MacGibbon, Kate P. Palmano, Dr Kislay Roy, Angela Rowan, Geoffrey W Krissansen

(2016), Vol. 99, pp. 2488-2501, Journal of dairy science, Atlanta, Ga., C1

journal

Probing the biophysical interaction between Neocarzinostatin toxin and EpCAM RNA aptamer

Mr Prasanna Kumar Athyala, Prof Jagat Kanwar, Mohamed Alameen, Dr Rupinder Kanwar, Dr Subramanian Krishnakumar, Prof Jon Watson, Umashankar Vetrivel, Dr Narayanan Janakiraman

(2016), Vol. 469, pp. 257-262, Biochemical and biophysical research communications, Amsterdam, The Netherlands, C1

journal

Amoebiasis vaccine development: a snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin

Ram Sarup Singh, Amandeep Kaur Walia, Prof Jagat Kanwar, John F Kennedy

(2016), Vol. 91, pp. 258-268, International journal of biological macromolecules, Amsterdam, The Netherlands, C1

journal

Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents

Mr Rajneesh Chaudhary, Dr Kislay Roy, Dr Rupinder Kanwar, Prof Ken Walder, Prof Jagat Kanwar

(2016), Vol. 14, pp. 1-17, Journal of nanobiotechnology, London, Eng., C1

journal

Antiparasitic and immunomodulatory potential of oral nanocapsules encapsulated lactoferrin protein against plasmodium berghei

Namrata Anand, Dr Rupinder Kanwar, Prof Rakesh Sehgal, Prof Jagat Kanwar

(2016), Vol. 11, pp. 47-62, Nanomedicine, London, Eng., C1

journal

Clinico-pathological association of delineated miRNAs in uveal melanoma with monosomy 3/Disomy 3 chromosomal aberrations

Nalini Venkatesan, Prof Jagat Kanwar, Perinkulam Ravi Deepa, Vikas Khetan, Dr Tamsyn Crowley, Miss Rajeswari Raguraman, Ganesan Sugneswari, Pukhraj Rishi, Viswanathan Natarajan, Jyotirmay Biswas, Dr Subramanian Krishnakumar

(2016), Vol. 11, pp. 1-14, PLoS one, San Francisco, Calif., C1

journal
2015

Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc

Prof Jagat Kanwar, Mr VNL Ganesh Mahidhara, Dr Kislay Roy, Sreenivasan Sasidharan, Dr Krishnakumar Subramanian, Neerati Prasad, Prof Rakesh Sehgal, Dr Rupinder Kanwar

(2015), Vol. 10, pp. 35-55, Nanomedicine, London, United Kingdom, C1

journal

YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

S M Cheng, Y C Chang, C Y Liu, J Y C Lee, H H Chan, C W Kuo, K Y Lin, S L Tsai, S H Chen, C F Li, E Leung, Prof Jagat Kanwar, C C Huang, J Y Chang, C H A Cheung

(2015), Vol. 172, pp. 214-234, British Journal of Pharmacology (Online), London, Eng., C1

journal

Lactoferrin induced neuronal differentiation: A boon for brain tumours.

Dr Bhasker Sriramoju, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 41, pp. 28-36, International Journal of Developmental Neuroscience, England, C1

journal

Cissus quadrangularis inhibits IL-1β induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling

Prof Jagat Kanwar, Dr Rasika Samarasinghe, Prof Kuldeep Kumar, Ramesh Arya, Sanjeev Sharma, Shu-Feng Zhou, Sreenivasan Sasidharan, Dr Rupinder Kanwar

(2015), Vol. 9, pp. 2927-2940, Drug Design, Development and Therapy, Auckland, N.Z., C1

journal

Nanoformulated mutant SurR9-C84A: a possible key for alzheimer's and its associated inflammation

Dr Bhasker Sriramoju, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 32, pp. 2787-2797, Pharmaceutical research, New York, N. Y., C1

journal

Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: promising potential for targeting radiosensitive retinoblastoma

Miss Jaisy Samuel, Mr Narinderbir Singh, Prof Jagat Kanwar, Subramanium Krishnakumar, Dr Rupinder Kanwar

(2015), Vol. 139, pp. 108-114, Experimental eye research, Amsterdam, The Netherlands, C1

journal

Brain targeted PLGA nanocarriers alleviating amyloid-Β expression and preserving basal survivin in degenerating mice model

Dr Bhasker Sriramoju, Neerati Prasad, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 1852, pp. 2423-2431, Biochimica et biophysica acta, Amsterdam, The Netherlands, C1

journal

LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging

Dr Kislay Roy, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 71, pp. 84-99, Biomaterials, Amsterdam, The Netherlands, C1

journal

Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer

Miss Jessica Gibbons, Prof Jagat Kanwar, Dr Rupinder Kanwar

(2015), Vol. 15, pp. 1-16, BMC cancer, London, Eng., C1

journal

Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery

Ms Nithya Subramanian, Prof Jagat Kanwar, Balachandran Akilandeswari, Dr Rupinder Kanwar, Vikas Khetan, Dr Subramanian Krishnakumar

(2015), Vol. 51, pp. 6940-6943, Chemical communications, Cambridge, Eng., C1

journal

Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism

Ganesh Mahidhara, Dr Rupinder Kanwar, Dr Kislay Roy, Prof Jagat Kanwar

(2015), Vol. 10, pp. 4081-4098, International journal of nanomedicine, Auckland, N. Z., C1

journal

EpCAM Aptamer-siRNA chimera targets and regress epithelial cancer

Ms Nithya Subramanian, Prof Jagat Kanwar, Dr Rupinder Kanwar, JagadeeshBabu Sreemanthula, Jyotirmay Biswas, Vikas Khetan, Dr Subramanian Krishnakumar

(2015), Vol. 10, pp. 1-19, PLoS one, San Francisco, Calif., C1

journal

Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite-host interaction

Namrata Anand, Dr Rupinder Kanwar, Mohan Dubey, R.K. Vahishta, Prof Rakesh Sehgal, Anita K. Verma, Prof Jagat Kanwar

(2015), Vol. 9, pp. 3821-3835, Drug design develeopment and therapy, Auckland, N.Z, C1

journal

Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition

Stacey Edwards, Vasanthanathan Poongavanam, Prof Jagat Kanwar, Dr Kislay Roy, Kristine Hillman, Neerati Prasad, Rikke Leth-Larsen, Michael Petersen, Maja Marusic, Janez Plavec, Jesper Wengel, Rakesh N Veedu

(2015), Vol. 51, pp. 9499-9502, Chemical Communications, London, Eng., C1

journal

Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

Dr Kislay Roy, Dr Rupinder Kanwar, Dr Subramanian Krishnakumar, Chun Hei Antonio Cheung, Prof Jagat Kanwar

(2015), Vol. 10, pp. 1019-1043, International journal of nanomedicine, Auckland, N. Z., C1

journal

Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma

Ms Nithya Subramanian, Prof Jagat Kanwar, Dr Rupinder Kanwar, Dr Subramanian Krishnakumar

(2015), Vol. 25, pp. 47-52, Nucleic acid therapeutics, New Rochelle, N. Y., C1

journal

Molecular targets in arthritis and recent trends in nanotherapy

Dr Kislay Roy, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 10, pp. 5407-5420, International journal of nanomedicine, Auckland, N. Z., C1

journal

Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells

Nihal Maremanda, Dr Kislay Roy, Dr Rupinder Kanwar, Vidyarani Shyamsundar, Vijayalakshmi Ramshankar, Arvind Krishnamurthy, Dr Subramanian Krishnakumar, Prof Jagat Kanwar

(2015), Vol. 9, pp. 1-20, Biomicrofluidics, Maryland, United States, C1

journal

Can cancer therapy be achieved by bridging apoptosis and autophagy: A method based on microRNA-dependent gene therapy and phytochemical targets

Soundararajan Vijayarathna, Sivapragasam Gothai, Subramanion L. Jothy, Yeng Chen, Prof Jagat Kanwar, Sreenivasan Sasidharan

(2015), Vol. 16, pp. 7435-7439, Asian pacific journal of cancer prevention, Bangkok, Asia, C1

journal

Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases

Dr Bhasker Sriramoju, Dr Rupinder Kanwar, Rakesh N Veedu, Prof Jagat Kanwar

(2015), Vol. 15, pp. 1115-1124, Current topics in medicinal chemistry, Bussum, The Netherlands, C1

journal

Nucleic acid-based aptamers: applications, development and clinical trials

Prof Jagat Kanwar, Dr Kislay Roy, Nihal Maremanda, Dr Krishnakumar Subramanian, Rakesh N Veedu, Raj Bawa, Dr Rupinder Kanwar

(2015), Vol. 22, pp. 2539-2557, Current medicinal chemistry, Bussum, The Netherlands, C1

journal

Evaluation of nanoformulated therapeutics in an ex-vivo bovine corneal irritation model

Dr Bhasker Sriramoju, Dr Kislay Roy, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 29, pp. 917-925, Toxicology in vitro, Amsterdam, The Netherlands, C1

journal

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

Ms Nithya Subramanian, Prof Jagat Kanwar, Prasanna Athalya, Dr Narayanan Janakiraman, Vikas Khetan, Dr Rupinder Kanwar, Sailaja Eluchuri, Dr Subramanian Krishnakumar

(2015), Vol. 22, pp. 1-10, Journal of biomedical science, London, Eng., C1

journal

Neurobehavioral burden of multiple sclerosis with nanotheranostics

Dr Bhasker Sriramoju, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2015), Vol. 11, pp. 2675-2689, Neuropsychiatric disease and treatment, Auckland, New Zealand, C1

journal

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Namrata Anand, Prof Rakesh Sehgal, Dr Rupinder Kanwar, Mohan Dubey, Rakesh Kumar Vasishta, Prof Jagat Kanwar

(2015), Vol. 10, pp. 6355-6369, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Targeting cancer cells using LNA-modified aptamer-siRNA chimeras

Ms Nithya Subramanian, Prof Jagat Kanwar, Dr Rupinder Kanwar, Dr Subramanian Krishnakumar

(2015), Vol. 25, pp. 317-322, Nucleic acid therapeutics, New Rochelle, N.Y., C1

journal

Ultra-small algal chitosan ocular nanoparticles with iron-binding milk protein prevents the toxic effects of carbendazim pesticide

Mr Pavan Sunkireddy, Dr Rupinder Kanwar, Jagat Ram, Prof Jagat Kanwar

(2015), Vol. 11, pp. 495-511, Nanomedicine, London England, C1

journal
2014

Current protein-based anti-angiogenic therapeutics

Sanjukta Chakrabarti, Prof Colin Barrow, Dr Rupinder Kanwar, Dr Venkata Ramana, Prof Jagat Kanwar

(2014), Vol. 14, pp. 291-312, Mini-reviews in medicinal chemistry, Bussum, The Netherlands, C1

journal

The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis

Dr Rasika Samarasinghe, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2014), Vol. 35, pp. 7522-7534, Biomaterials, Amsterdam, The Netherlands, C1

journal

Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases

Prof Jagat Kanwar, Mr Jayanth Surya Narayanan Shankara Narayanan, Ms Sneha Gurudevan, Dr Rupinder Kanwar

(2014), Vol. 19, pp. 1309-1321, Drug discovery today, Amsterdam, The Netherlands, C1

journal

A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells

Ms Nithya Subramanian, Jagadeesh Babu Sreemanthula, Baghavathi Balaji, Prof Jagat Kanwar, Jyotirmay Biswas, Dr Subramanian Krishnakumar

(2014), Vol. 50, pp. 11810-11813, Chemical Communications, Cambridge, England, C1

journal

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies

Zhi-Xin Wang, Jiazi Sun, Caitlin E Howell, Qing-Yu Zhou, Zhi-Xu He, Tianxin Yang, Helen Chew, Prof Wei Duan, Zhi-Wei Zhou, Prof Jagat Kanwar, Shu-Feng Zhou

(2014), Vol. 28, pp. 551-582, Fundamental & Clinical Pharmacology, Abingdon, England, C1

journal

Nanoformulated cell-penetrating survivin mutant and its dual actions

Dr Bhasker Sriramoju, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2014), Vol. 9, pp. 3279-3298, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Nanomedicine based nanoparticles for neurological disorders

Mr Bhasker Sriramoju, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2014), Vol. 21, pp. 4154-4168, Current medicinal chemistry, Bussum, Netherlands, C1

journal

MicroRNA pathways : an emerging role in identification of therapeutic strategies

Soundararajan Vijayarathna, Chern E. Oon, Subramanion L. Jothy, Yeng Chen, Prof Jagat Kanwar

(2014), Vol. 14, pp. 112-120, Current Gene Therapy, Bussum, Netherlands, C1

journal

Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism

Miss Isha Gupta, Prof Rakesh Sehgal, Dr Rupinder Kanwar, Dr Vasu Punj, Prof Jagat Kanwar

(2014), pp. 1-26, Nanomedicine, London, United Kingdom, C1

journal

Bioceramic nanomaterials in medical applications

Prof Jagat Kanwar, Ganesh Mahidhara, Dr Kislay Roy, Dr Rupinder Kanwar

(2014), pp. 163-175, Bioengineered nanomaterials, Boca Raton, Flo., B1

chapter

Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers

Ms Neha Singh, Dr Subramanian Krishnakumar, Dr Rupinder Kanwar, Chun Hei Antonio Cheung, Prof Jagat Kanwar

(2014), Vol. 20, pp. 578-587, Drug discovery today, London, Eng., C1

journal
2013

Survivin signaling in clinical oncology : a multifaceted dragon

Prof Jagat Kanwar, Mr Sishir Kumar Kamalapuram, Dr Rupinder Kanwar

(2013), Vol. 33, pp. 765-789, Medicinal research reviews, London, England, C1

journal

Generating different profiles of gradient concentrations inside a gel-filled chamber : design and simulation

Mrs Masoomeh Tehrani Rokh, Prof Abbas Kouzani, Prof Paul Francis, Prof Jagat Kanwar

(2013), Vol. 19, pp. 623-628, Microsystem technologies, Berlin, Germany, C1

journal

Synthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatment

Juan-Juan Yin, Sonali Sharma, Stepan P Shumyak, Zhi-Xin Wang, Zhi-Wei Zhou, Yangde Zhang, Peixuan Guo, Chen-Zhong Li, Prof Jagat Kanwar, Tianxin Yang, Prof Shyam S. Mohapatra, Wanqing Liu, Prof Wei Duan, Jian-Cheng Wang, Qi Li, Xueji Zhang, Jun Tan, Lee Jia, Jun Liang, Ming Qian Wei, Xiaotian Li, Shu-Feng Zhou

(2013), Vol. 8, pp. 1-20, PLOS one, San Francisco, California, C1

journal

Microfluidic devices for cell cultivation and proliferation

Mrs Masoomeh Tehrani Rokh, Prof Abbas Kouzani, Prof Paul Francis, Prof Jagat Kanwar

(2013), Vol. 7, pp. 1-32, Biomicrofluidics, Melville, N.Y., C1

journal

RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma

Ms Nithya Subramanian, Saranya Navaneethakrishnan, Jyotirmay Biswas, Dr Rupinder Kanwar, Prof Jagat Kanwar, Dr Subramanian Krishnakumar

(2013), Vol. 8, pp. e70422-, PLoS One, San Francisco, CA, C1

journal

Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer

Dr Rupinder Kanwar, Prof Jagat Kanwar

(2013), Vol. 20, pp. 450-458, Protein & peptide letters, Bussum, The Netherlands, C1

journal
2012

A novel nanoplatform for oral delivery of anti-cancer biomacromolecules

Mr VNL Ganesh Mahidhara, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2012), Vol. 9, pp. 942-960, International journal of nanotechnology, Olney, England, C1

journal

Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer

Lixin Ma, Haiquan Qiao, Changjun He, Qian Yang, Chun Hei Antonio Cheung, Prof Jagat Kanwar, Xueying Sun

(2012), Vol. 30, pp. 508-517, Investigational new drugs, New York, N.Y., C1

journal

Herb-drug interactions and mechanistic and clinical considerations

Xiao-Wu Chen, Kevin B Sneed, Si-Yuan Pan, Chuanhai Cao, Prof Jagat Kanwar, Helen Chew, Shu-Feng Zhou

(2012), Vol. 13, pp. 640-651, Current drug metabolism, Hilversum, The Netherlands, C1

journal

Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis : how far have we come?

Dr Rupinder Kanwar, Mr Rajneesh Chaudhary, Dr Takuya Tsuzuki, Prof Jagat Kanwar

(2012), Vol. 7, pp. 899-916, Nanomedicine, London, England, C1

journal

The antimicrobial efficacy of elaeis guineensis : characterization, in Vitro and in Vivo studies

Soundararajan Vijayarathna, Zuraini Zakaria, Yeng Chen, Lachimanan Yoga Latha, Prof Jagat Kanwar, Sreenivasan Sasidharan

(2012), Vol. 17, pp. 4860-4877, Molecules, Basel, Switzerland, C1

journal

Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide

Prof Jagat Kanwar, Miss Jessica Gibbons, Anita K. Verma, Dr Rupinder Kanwar

(2012), Vol. 23, pp. 471-482, Anti-cancer drugs, Philadelphia, Pa., C1

journal

Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells

Prof Jagat Kanwar, Dr Rupinder Kanwar, Mr VNL Ganesh Mahidhara, Hei Chun Antonio Cheung

(2012), Vol. 65, pp. 5-14, Australian journal of chemistry, Collingwood, VIC., C1

journal

Gradient generating microfluidic devices for cell cultivation

Mrs Masoomeh Tehrani Rokh, Prof Abbas Kouzani, Prof Jagat Kanwar

(2012), Vol. 29, pp. 1740-1744, Procedia engineering, Amsterdam, Netherlands, C1

journal

Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases

Prof Jagat Kanwar, Dr Rasika Samarasinghe, Prof Rakesh Sehgal, Dr Rupinder Kanwar

(2012), Vol. 4, pp. 31-42, Journal of cancer science & therapy, Westlake, Calif., C1-1

journal

The role of nanomedicine in cell based therapeutics in cancer and inflammation.

Dr Rasika Samarasinghe, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2012), Vol. 1, pp. 133-144, International journal of molecular and cellular medicine, Babol, Iran, C1-1

journal

Novel alginate-enclosed chitosan–calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy

Prof Jagat Kanwar, Ganesh Mahidhara, Dr Rupinder Kanwar

(2012), Vol. 7, pp. 1521-1550, Nanomedicine, London, England, C1

journal

Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer

Ms Nithya Subramanian, Vaishnavi Raghunathan, Prof Jagat Kanwar, Dr Rupinder Kanwar, Sailaja V. Elchuri, Vikas Khetan, Dr Subramanian Krishnakumar

(2012), Vol. 18, pp. 2783-2795, Molecular vision, Atlanta, Ga., C1

journal

Nanotechnology based platforms for survivin targeted drug discovery

Dr Rasika Samarasinghe, Miss Jessica Gibbons, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2012), Vol. 7, pp. 1083-1092, Expert opinion on drug discovery, London, England, C1

journal

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

Prof Jagat Kanwar, Dr Bhasker Sriramoju, Dr Rupinder Kanwar

(2012), Vol. 7, pp. 3259-3278, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages

Dr Rupinder Kanwar, Mr Rajneesh Chaudhary, Dr Takuya Tsuzuki, Prof Jagat Kanwar

(2012), Vol. 7, pp. 735-749, Nanomedicine, London, England, C1

journal

TH17 cells in cancer related inflammation

Dr Rupinder Kanwar, Prof Jagat Kanwar

(2012), pp. 43-60, Recent advances in immunology to target cancer, inflammation and infections, Rijeka, Croatia, B1-1

chapter

Immunology of Leishmaniasis and future prospective of vaccines

Prof Rakesh Sehgal, Kapil Goyal, Dr Rupinder Kanwar, Alka Sehgal, Prof Jagat Kanwar

(2012), pp. 479-494, Recent advances in immunology to target cancer, inflammation and infections, Rijeka, Croatia, B1-1

chapter

Milk proteins and human health

Prof Jagat Kanwar, Dr Rupinder Kanwar, Dr Munish Puri

(2012), pp. 1-1, Food biotechnology : principles and practices, New Delhi, India, B1-1

chapter

Structure, rhelogy and texturization of food proteins

Dr Munish Puri, Mr Parveen Pahuja, Prof Jagat Kanwar

(2012), pp. 1-1, Food biotechnology : principles and practices, India, B1-1

chapter
2011

Nanoparticles in the treatment and diagnosis of neurological disorders : untamed dragon with fire power to heal

Prof Jagat Kanwar, Xueying Sun, Dr Vasu Punj, Dr Bhasker Sriramoju, Prof Rajiv R. Mohan, Shu-Feng Zhou, Ashok Chauhan, Dr Rupinder Kanwar

(2011), Vol. 8, pp. 399-414, Nanomedicine : nanotechnology, biology and medicine, Philadelphia, Pa., C1

journal

Antioxidant enzyme activities of iron-saturated bovine lactoferrin (Fe-bLf) in human gut epithelial cells under oxidative stress

Ms Hannah Burrow, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2011), Vol. 7, pp. 224-230, Medicinal chemistry, Bussum, Netherlands, C1

journal

Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress

Ms Sara Baratchi, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2011), Vol. 6, pp. 1-8, PLoS ONE, San Francisco, Ca., C1

journal

Targeting survivin in cancer : the cell-signalling perspective

Prof Jagat Kanwar, Mr Sishir Kumar Kamalapuram, Dr Rupinder Kanwar

(2011), Vol. 16, pp. 485-494, Drug Discovery Today, London, United Kingdom, C1

journal

Molecular weight and secondary structure change in eri silk during alkali degumming and powdering

Dr Rangam Rajkhowa, Dr Lijing Wang, Prof Jagat Kanwar, Prof Xungai Wang

(2011), Vol. 119, pp. 1339-1347, Journal of applied polymer science, Hoboken, N. J., C1

journal

Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)

Shu-Ming He, Songshu Li, Prof Jagat Kanwar, Shu-Feng Zhou

(2011), Vol. 18, pp. 439-481, Current medicinal chemistry, Bussum, Netherlands, C1

journal

Antiangiogenic therapy using nanotechnological-based delivery system

Prof Jagat Kanwar, Mr VNL Ganesh Mahidhara, Dr Rupinder Kanwar

(2011), Vol. 16, pp. 188-202, Drug discovery today, London, England, C1

journal

Viral RNA silencing suppressors (RSS) : novel strategy of viruses to ablate the host RNA interference (RNAi) defense system

Shalmali Bivalkar-Mehla, Janaki Vakharia, Rajeev Mehla, Measho Abreha, Prof Jagat Kanwar, Akshay Tikoo, Ashok Chauhan

(2011), Vol. 155, pp. 1-9, Virus research, Amsterdam, Netherlands, C1

journal

Receptor mediated tumor targeting : an emerging approach for cancer therapy

Chandana Mohanty, Manasi Das, Prof Jagat Kanwar, Sanjeeb K. Sahoo

(2011), Vol. 8, pp. 45-58, Current drug delivery, Bussum, Netherlands, C1

journal

Lactoferrin and cancer in different cancer models

Miss Jessica Gibbons, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2011), Vol. S3, pp. 1080-1088, Frontiers in Bioscience, Albertson, N.Y., C1

journal

Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity

Ms Sara Baratchi, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2011), Vol. 233, pp. 18-28, Journal of neuroimmunology, Amsterdam, Netherlands, C1

journal

Structure and properties of biomedical films prepared from aqueous and acidic silk fibroin solutions

Dr Rangam Rajkhowa, Brett Levin, Sharon Leanne Redmond, Dr Luhua Li, Dr Lijing Wang, Prof Jagat Kanwar, Prof Marcus Atlas, Prof Xungai Wang

(2011), Vol. 97A, pp. 37-45, Journal of biomedical materials research : Part A, Hoboken, N.J., C1

journal

Targeting hepatitis B virus and human papillomavirus induced carcinogenesis : novel patented therapeutics

Dr Rupinder Kanwar, Ms Neha Singh, Ms Sneha Gurudevan, Prof Jagat Kanwar

(2011), Vol. 6, pp. 158-174, Recent patents on anti-infective drug discovery, Bussum, Netherlands, C1

journal

Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma

Prof Jagat Kanwar, Ms Neha Singh, Dr Rupinder Kanwar

(2011), Vol. 6, pp. 701-714, Nanomedicine, London, England, C1

journal

The use of cyclodextrins nanoparticles for oral delivery

Prof Jagat Kanwar, B. M. Long, Dr Rupinder Kanwar

(2011), Vol. 18, pp. 2079-2085, Current medicinal chemistry, Hilversum, The Netherlands, C1

journal

Toll like receptors play a role in general immunity, eye infection and inflammation : TLRs for nanodelivery

Prof Jagat Kanwar, Shu-Feng Zhou, Ms Sneha Gurudevan, Prof Colin Barrow, Dr Rupinder Kanwar

(2011), Vol. 2, pp. 1-10, Journal of clinical and cellular immunology, Los Angeles, Calif., C1

journal

Chimeric aptamers in cancer cell-targeted drug delivery

Prof Jagat Kanwar, Dr Kislay Roy, Dr Rupinder Kanwar

(2011), Vol. 46, pp. 459-477, Critical reviews in biochemistry and molecular biology, London, England, C1

journal

Effect of selenium-saturated bovine lactoferrin (Se-bLF) on antioxidant enzyme activities in human gut epithelial cells under oxidative stress

Ms Hannah Burrow, Dr Rupinder Kanwar, Mr VNL Ganesh Mahidhara, Prof Jagat Kanwar

(2011), Vol. 11, pp. 762-771, Anti-cancer agents in medicinal chemistry, Bussum, Netherlands, C1

journal

Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats

Gang Tan, Shangha Pan, Jie Li, Xuesong Dong, Kai Kang, Mingyan Zhao, Xian Jiang, Prof Jagat Kanwar, Haiquan Qiao, Hongchi Jiang, Xueying Sun

(2011), Vol. 6, pp. 1-10, Plos one, San Francisco, Calif., C1

journal

Mitomycin C: a promising agent for the treatment of canine corneal scarring

R. Gupta, Benjamin W Yarnall, Elizabeth A Giuliano, Prof Jagat Kanwar, Dylan g. Buss, Prof Rajiv R. Mohan

(2011), Vol. 14, pp. 304-312, Veterinary ophthalmology, London, England, C1-1

journal
2010

Recent advances in anti-survivin treatments for cancer

Dr Rupinder Kanwar, Chun Hei Antonio Cheung, J. Y. Chang, Prof Jagat Kanwar

(2010), Vol. 17, pp. 1509-1515, Current medicinal chemistry, Hilversum, The Netherlands, C1

journal

Applications of nanomedicine in antibacterial medical therapeutics and diagnostics

Liam Matthews, Dr Rupinder Kanwar, Shu-Feng Zhou, Dr Vasu Punj, Prof Jagat Kanwar

(2010), Vol. 3, pp. 1-9, Open tropical medicine journal, Amsterdam, The Netherlands, C1-1

journal

Survivin : a target from brain cancer to neurodegenerative disease

Ms Sara Baratchi, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2010), Vol. 45, pp. 535-554, Critical reviews in biochemistry and molecular biology, London, England, C1

journal

Targeting survivin in cancer : patent review

Prof Jagat Kanwar, Mr Sishir Kumar Kamalapuram, Dr Rupinder Kanwar

(2010), Vol. 20, pp. 1723-1737, Expert opinion on therapeutic patents, London, England, C1

journal

Therapeutic effects of matrine on primary and metastatic breast cancer

Hali Li, Gang Tan, Xian Jiang, Haiquan Qiao, Shangha Pan, Hongchi Jiang, Prof Jagat Kanwar, Xueying Sun

(2010), Vol. 38, pp. 1115-1130, The American journal of Chinese medicine, Toh Tuck Link, Singapore, C1

journal

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

Chun Hei Antonio Cheung, Xueying Sun, Prof Jagat Kanwar, Ji-Zhong Bai, Li-Ting Cheng, Geoffrey W Krissansen

(2010), Vol. 10, pp. 1-11, Cancer cell international, London, England, C1

journal

MicroRNA in human cancer and chronic inflammatory diseases

Prof Jagat Kanwar, Mr VNL Ganesh Mahidhara, Dr Rupinder Kanwar

(2010), Vol. 2, pp. 1113-1126, Frontiers in bioscience (scholar edition), Albertson, N.Y., C1

journal

Recent advances on the possible neuroprotective activities of Epstein-Barr virus oncogene BARF1 protein in chronic inflammatory disorders of central nervous system

Ms Alicia Wynne, Dr Rupinder Kanwar, Rajiv Khanna, Prof Jagat Kanwar

(2010), Vol. 8, pp. 268-275, Current neuropharmacology, Sharjah, United Arab Emirates, C1

journal

Proliferative and protective effects of SurR9-C84A on differentiated neural cells.

Ms Sara Baratchi, Dr Rupinder Kanwar, Chun Hei Antonio Cheung, Prof Jagat Kanwar

(2010), Vol. 227, pp. 120-132, Journal of neuroimmunology, Amsterdam, Netherlands, C1

journal

Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases

Prof Jagat Kanwar, Prof Rajiv R. Mohan, Dr Rupinder Kanwar, Dr Kislay Roy, Raj Bawa

(2010), Vol. 5, pp. 1435-1445, Nanomedicine, London, England, C1

journal

Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice

Hongchi Jiang, Weiyang Tao, Mu Zhang, Shangha Pan, Prof Jagat Kanwar, Xueying Sun

(2010), Vol. 28, pp. 74-84, Cancer investigation, New York, N.Y., C1

journal

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells

Chun Hei Antonio Cheung, Huang-Hui Chen, Li-Ting Cheng, Kevin W. Lyu, Prof Jagat Kanwar, Jang-Yang Chang

(2010), Vol. 9, pp. 1-11, Molecular cancer, London, England, C1

journal

Cell disruption optimization and covalent immobilization of beta-D-galactosidase from kluyveromyces marxianus YW-1 for lactose hydrolysis in milk

Dr Munish Puri, Sabrina Gupta, Mr Parveen Pahuja, Aneet Kaur, Prof Jagat Kanwar, J F Kennedy

(2010), Vol. 160, pp. 98-108, Applied biochemistry and biotechnology, Totowa, United States, C1

journal
2009

Fabrication of ultrafine powder from eri silk through attritor and jet milling

Dr Rangam Rajkhowa, Dr Lijing Wang, Prof Jagat Kanwar, Prof Xungai Wang

(2009), Vol. 191, pp. 155-163, Powder technology, Lausanne, Switzerland, C1

journal

Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal

Prof Jagat Kanwar, Dr Rupinder Kanwar

(2009), Vol. 10, pp. 1-19, BMC immunology, London, England, C1

journal

Recent advances in nanoneurology for drug delivery to the brain

Prof Jagat Kanwar, Dr Rupinder Kanwar, Mr VNL Ganesh Mahidhara

(2009), Vol. 5, pp. 441-447, Current nanoscience, Bussum, Netherlands, C1

journal

Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6

Sui-Lin Mo, Ya-He Liu, Prof Wei Duan, Ming Qian Wei, Prof Jagat Kanwar, Shu-Feng Zhou

(2009), Vol. 10, pp. 730-753, Current drug metabolism, Hilversum, The Netherlands, C1

journal

Recent advances on the roles of NO in cancer and chronic inflammatory disorders

Prof Jagat Kanwar, Dr Rupinder Kanwar, Ms Hannah Burrow, Ms Sara Baratchi

(2009), Vol. 16, pp. 2373-2394, Current medicinal chemistry, Bussum, Netherlands, C1

journal

Ribosome inactivating proteins (RIPs) from momordica charantia for anti viral therapy

Dr Munish Puri, Inderdeep Kaur, Dr Rupinder Kanwar, Rita Gupta, Ashok Chauhan, Prof Jagat Kanwar

(2009), Vol. 9, pp. 1080-1094, Current molecular medicine, Bussum, Netherlands, C1

journal

Recent advances of metal binding protein lactoferrin as an anti-microbial agent

Miss Isha Gupta, Dr Rupinder Kanwar, Prof Jagat Kanwar

(2009), Vol. 5, pp. 226-233, Current bioactive compounds, Bussum, Netherlands, C1

journal

Molecular and biotechnological advances in milk proteins in relation to human health

Prof Jagat Kanwar, Dr Rupinder Kanwar, Dr Vasu Punj, Hittu Matta, Somasundaram M. Morley, Prof Andrew Parratt, Dr Munish Puri

(2009), Vol. 10, pp. 308-338, Current protein and peptide science, Bussum, Netherlands, C1

journal
2008

Bovine milk fat enriched in conjugated linoleic and vaccenic acids attenuates allergic airway disease in mice

Dr Rupinder Kanwar, Alister MacGibbon, Peter Black, Prof Jagat Kanwar, Angela Rowan, Molly Vale, Geoffrey W Krissansen

(2008), Vol. 38, pp. 208-218, Clinical and experimental allergy, Oxford, England, C1

journal

'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy

Prof Jagat Kanwar, Kate P. Palmano, Xueying Sun, Dr Rupinder Kanwar, Rita Gupta, Neill Haggarty, Angela Rowan, Satyendra Ram, Geoffrey W Krissansen

(2008), Vol. 86, pp. 277-288, Immunology and cell biology, London, England, C1

journal

Immobilized enzyme technology for debittering citrus fruit juices

Dr Munish Puri, Aneet Kaur, Ram Sarup Singh, Prof Jagat Kanwar

(2008), pp. 91-103, Food enzymes : application of new technologies, Kerala, India, B1

chapter
2006

Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas

Liqiong Luo, Haiquan Qiao, Fanqiang Meng, Xuesong Dong, Baoguo Zhou, Hongchi Jiang, Prof Jagat Kanwar, Geoffrey W Krissansen, Xueying Sun

(2006), Vol. 118, pp. 1823-1830, International journal of cancer, Malden, Mass., C1-1

journal

A pseudosymmetric cell adhesion regulatory domain in the β7 tail of the integrin α4β7 that interacts with focal adhesion kinase and src

Geoffrey W Krissansen, Jaison Singh, Dr Rupinder Kanwar, Yih-Chih Chan, Euphemia Leung, Klaus B Lehnert, Prof Jagat Kanwar, Yi Yang

(2006), Vol. 36, pp. 2203-2214, European journal of immunology, Weinheim, Germany, C1-1

journal
2005

Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease

Prof Jagat Kanwar

(2005), Vol. 12, pp. 2947-2962, Current medicinal chemistry, Bussum, Netherlands, C1-1

journal
2004

Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis

Prof Jagat Kanwar, Dr Rupinder Kanwar, Geoffrey W Krissansen

(2004), Vol. 127, pp. 1313-1331, Brain : a journal of neurology, Oxford, England, C1-1

journal

Bioassay detects soluble MAdCAM-1 in body fluids

Euphemia Leung, Klaus B Lehnert, Prof Jagat Kanwar, Yi Yang, Yu Mon, H. Patrick McNeil, Geoffrey W Krissansen

(2004), Vol. 82, pp. 400-409, Immunology and cell biology, Basingstoke, England, C1-1

journal
2003

Mucosal vascular addressin cell adhesion molecule-1 is expressed outside the endothelial lineage on fibroblasts and melanoma cells

Euphemia Leung, Dr Rupinder Kanwar, Prof Jagat Kanwar, Geoffrey W Krissansen

(2003), Vol. 81, pp. 320-327, Immunology and cell biology, Basingstoke, England, C1-1

journal

Mouse B7-H3 induces antitumor immunity

Xueying Sun, Molly Vale, Euphemia Leung, Prof Jagat Kanwar, Rita Gupta, Geoffrey W Krissansen

(2003), Vol. 10, pp. 1728-1734, Gene therapy, London, England, C1-1

journal

Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha

Xueying Sun, Prof Jagat Kanwar, Euphemia Leung, Molly Vale, Geoffrey W Krissansen

(2003), Vol. 10, pp. 2081-2089, Gene Therapy, London, England, C1-1

journal

Requirements for ICAM-1 immunogene therapy of lymphoma.

Prof Jagat Kanwar, Randy W. Berg, Yi Yang, Dr Rupinder Kanwar, Lai-Ming Ching, Xueying Sun, Geoffrey W Krissansen

(2003), Vol. 10, pp. 468-476, Cancer gene therapy, London, England, C1-1

journal
2001

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci

Prof Jagat Kanwar, Dr Rupinder Kanwar, Sushil Pandey, Lai-Ming Ching, Geoffrey W Krissansen

(2001), Vol. 61, pp. 1948-1956, Cancer research, Birmingham, Ala., C1-1

journal

Effects of survivin antagonists of growth of established tumors and B7-1 immunogene therapy

Prof Jagat Kanwar, Wei-Ping Shen, Dr Rupinder Kanwar, Randy W. Berg, Geoffrey W Krissansen

(2001), Vol. 93, pp. 1541-1552, Journal of the National Cancer Institute, Oxford, England, C1-1

journal

Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice

Dr Rupinder Kanwar, Prof Jagat Kanwar, Dongmao wang, Douglas J. Ormrod, Geoffrey W Krissansen

(2001), Vol. 21, pp. 1991-1997, Arteriosclerosis thrombosis and vascular biology, Philadelphia, Pa., C1-1

journal
2000

Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression.

Prof Jagat Kanwar, Dr Rupinder Kanwar, Dongmao wang, Geoffrey W Krissansen

(2000), Vol. 78, pp. 641-645, Immunology and cell biology, London, England, C1-1

journal
1996

In vitro production of Campylobacter jejuni enterotoxin (CJT) and its characterization through biological assays

Rupinder Kaur, Ajit Singh, Prof Jagat Kanwar, Mahinder S Kalra

(1996), Vol. 31, pp. 427-431, Journal of research : Punjab Agricultural University, Ludhiana, India, C1-1

journal
1994

Purification and partial immunochemical characterization of a low molecular mass, diagnostic Echinococcus granulosus immunogen for sheep hydatidosis

Prof Jagat Kanwar, Dr Rupinder Kanwar

(1994), Vol. 9, pp. 101-107, FEMS immunology & medical microbiology, Oxford, England, C1-1

journal

Impairment of Na+,K+-ATPase activity following enterotoxigenic Campylobacter jejuni infection: changes in Na+, Cl-- and 3-O-methyl-D-glucose transport in vitro, in rat ileum

Dr Rupinder Kanwar, Nirmal K Ganguly, Prof Jagat Kanwar, Lata Kumar, B NS Walia

(1994), Vol. 124, pp. 381-385, FEMS microbiology letters, Oxford, England, C1-1

journal

Significance of detection of immune-complexed 8 kDa hydatid-specific antigen for immunodiagnosis of hydatidosis

Prof Jagat Kanwar, Dr Rupinder Kanwar, A S Grewal, V K Vinayak

(1994), Vol. 9, pp. 231-236, FEMS immunology & medical microbiology, Oxford, England, C1-1

journal